CEO of Topotarget to resign

CEO Anders Vadsholt will resign at the end of July, 2014 or at the latest until the approval of the merger with BioAlliance Pharma


Topotarget today announced that Anders Vadsholt will resign his position as CEO of Topotarget. Anders has been CEO since August 30, 2012 and will continue in his present position until 31 July 2014 or at the latest until the expected approval of the merger.

As earlier announced, the CEO of BioAlliance Pharma, Judith Greciet, will take over the position as CEO of the combined company, OnXeo, when the merger is approved.

Topotarget’s Chairman of the Board of Directors Bo Jesper Hansen comments; "We wish Anders the best of luck and would also like to thank him for the great efforts he has made during his time at Topotarget" 

 

Topotarget A/S

For further information, please contact:

Bo Jesper Hansen, Chairman of the Board of Directors

+45 26 12 83 84

Anders Vadsholt, Chief Executive Officer

+45 28 98 90 55

About Topotarget

Topotarget (NASDAQ OMX: TOPO) is a Danish-based biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy. For more information, please refer to http://www.topotarget.com/